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Abstract: We report on the electrochemical detection of anti-cancer drugs in human serum 
with sensitivity values in the range of 8–925 nA/µM. Multi-walled carbon nanotubes were 
functionalized with three different cytochrome P450 isoforms (CYP1A2, CYP2B6, and 
CYP3A4). A model used to effectively describe the cytochrome P450 deposition onto 
carbon nanotubes was confirmed by Monte Carlo simulations. Voltammetric measurements 
were performed in phosphate buffer saline (PBS) as well as in human serum, giving  
well-defined current responses upon addition of increasing concentrations of anti-cancer 
drugs. The results assert the capability to measure concentration of drugs in the 
pharmacological ranges in human serum. Another important result is the possibility to 
detect pairs of drugs present in the same sample, which is highly required in case of 
therapies with high side-effects risk and in anti-cancer pharmacological treatments based 
on mixtures of different drugs. Our technology holds potentials for inexpensive multi-panel 
drug-monitoring in personalized therapy. 
Keywords: cytochrome P450; carbon-nanotubes; electrochemical drugs detection;  
breast-cancer; human serum; personalized therapy 
 
1. Introduction 
The rising demand for the development of personalized therapy has recently stimulated significant 
research in investigating electrochemical biosensors based on cytochrome P450 for detection of drugs 
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and other chemical compounds [1]. The detection mechanism of these enzymatic amperometric 
biosensors is the measurement of the current produced at the electrode surface due to the redox 
reaction of the enzyme when a substrate is present in the sample. Cytochrome P450 enzymes (CYPs) 
have widely been used as recognition elements for the construction of amperometric biosensors [1,2] 
due to the ability of these enzymes to metabolize a wide range of endogenous substances and 
exogenous compounds, such as drugs and environmental toxins [3]. A cytochrome P450 biosensor is a 
promising technology that can provide quick measurements for concentrations of drugs and 
metabolites with good selectivity, accuracy, sensitivity and low-cost equipment. The immobilization of 
CYP onto the electrode surface has to be accurately controlled in order to obtain a high probability for 
the protein to be attached to the electrode in a proper orientation so that the electron transfer from the 
active site of the enzyme is optimized [2,4]. 
Several attempts have been made to measure drug concentration with P450-based systems [1,2,5–8], 
but the development of a biosensor capable of measuring a drug mixture is still an open problem. 
Multiple drug detection with cytochromes P450 is a challenging task because CYP isoforms are not 
selective for a single compound, and are subject to several atypical kinetic features [9,10] that can 
affect the protein efficiency according to the concentration and the drug molecules present in the sample.  
Different kinds of nano-structures, such as nano-particles, have been extensively employed for 
improving the CYP-biosensors selectivity and sensitivity [11–16]. Carbon nanotubes (CNTs) have 
been recognized as a very promising layer for enhancing electron transfer [17], thanks to their 
electrical and electrochemical properties, which make them suitable to be integrated into biological 
sensors. For these applications, carbon nanotubes exhibit some advantages: small size with large 
surface, high conductivity, high chemical stability and sensitivity [18], high electrocatalytic effect and 
a fast electron-transfer rate [19]. Recent studies demonstrate that CNTs can enhance the 
electrochemical reactivity of proteins or enzymes with retention of their biocatalytic activity [17,20].  
In this work we develop biosensors based on microsomal cytochrome P450 and nanostructured  
with multi-walled carbon-nanotubes to electrochemically detect drugs used in the treatment of  
breast-cancer. In order to investigate the feasibility of P450-based sensors for clinical applications, we 
focused on chemotherapy treatments for breast cancer. In many cases, chemotherapy medicines are 
given in combination, i.e., two or three medicines administered at the same time [21]. These 
combinations are known as chemotherapy regimens [22]. After having considered the pharmacological 
range for various drugs, we selected four compounds: cyclophosphamide, etoposide, ftorafur, and 
ifosfamide. These four drugs have been chosen because they have sufficiently high and wide 
pharmacological ranges, which are compatible with the detection limit of the measurement setup. 
For the specific detection of these drugs, we employed three different cytochrome P450 isoforms, 
the CYP1A2, CYP2B6 and CYP3A4; recent studies [23,24] suggest that cytochrome P4503A4 and 
CYP2B6 may be the major enzymes catalyzing the 4-hydroxylation of cyclophosphamide and 
ifosfamide; CYP1A2 is known to catalyze the biocativation of ftorafur [25,26]; other studies reported 
that CYP3A4 and CYP1A2 enzymes are involved in etoposide O-demethylation [27].  
The main contributions presented in this paper include: (1) a model for describing the protein 
absorption onto CNTs, confirmed by numerical simulations as well as scanning electron microscopy 
analysis; (2) drugs detection within the therapeutic range in human serum; and (3) the detection of two 
drugs present in the sample at the same time. The results demonstrate that the nanostructure of the 
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deposited enzyme and CNT on the electrodes enables to lower the limit of drug detection to fit the 
therapeutic range even in human serum. Consequently, we prove that the proposed method is suitable 
for drug monitoring for applications in personalized therapy. 
2. Experimental Section 
2.1. Materials 
The biosensor was fabricated by using commercially available carbon paste screen-printed 
electrodes (SPE model DRP-110, purchased from DropSens, Llanera, Spain), made of a graphite 
working electrode (area, 12.56 mm2), a graphite counter electrode and an Ag/AgCl reference electrode. 
Multi walled carbon nanotubes (MWCNT, diameter 10 nm, length 1–2 μm, with 5% –COOH groups 
content), purchased in powders from DropSens were diluted in chloroform to the fixed concentration 
of 1 mg/mL and then sonicated for 30 min in order to obtain a homogeneous suspension breaking 
macro-aggregates. Cytochromes P4503A4 and 1A2 (from Sigma-Aldrich, St. Gallen, Switzerland), 
and cytochrome P4502B6 (from BD Bioscience, Franklin Lakes, NJ, USA), were purchased as 
isozyme microsomes with P450 reductase and cytochrome b5, recombinant, expressed in baculovirus 
infected insect cells (BTI-TN-5B1-4). Microsomes were given in solution in 100 mM phosphate buffer 
saline (PBS, from Sigma-Aldrich), at pH 7.4 and used without modifications. All the drugs, 
cyclophosphamide, ifosfamide, ftorafur and etoposide, were purchased in powder from Sigma-Aldrich. 
Cyclophosphamide, Ifosfamide, Ftorafur were dissolved in Milli-Q water. Etoposide was dissolved in 
dimethyl sulfoxide (DMSO) due to its low solubility in water. PBS 100 mM (10×, pH 7.4) and human 
serum were used as supporting electrolytes. Human serum was purchased from Lonza (Basel, 
Switzerland) and used without any dilution. 
2.2. Preparation of Nano-Structured Electrodes  
The CNT solution (30 μL) was gradually deposited by drop-casting onto the working electrode. 
After each single deposition, the chloroform evaporates and the nanotubes lay down on the electrode 
surface forming a 3D porous nanostructure. The P450 solution (usually 9 μL of solution for each 
protein layer) was spread onto the CNT-electrode surface and incubated at 4 °C overnight, to allow the 
protein to be homogeneously adsorbed onto the CNTs-nanostructure. This procedure was repeated for 
every P450 deposition after having incubated electrodes for 8 h at 4 °C. All the functionalized 
electrodes were stored at +4 °C and covered with PBS when not used.  
2.3. Surface Imaging 
Morphological analysis of the nano-structured electrodes was carried out using a Philips/FEI  
XL-30F microscope (Eindhoven, The Netherlands) to acquire Scanning Electron Microscope (SEM) 
images for bare and nano-structured electrodes. Scanning electron microscope operating in ultra-high 
resolution mode (UHR), with a working distance in the range 1.5–4.2 mm, was used to analyze the 
morphology of electrode surface after the modification with MWCNTs and cytochrome P450 
solutions. The resolution in UHR mode is 2.5 nm at 1 kV. 
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2.4. Electrochemical Measurements 
All electrochemical measurements were performed using a Versastat 3 potentiostat (Princeton 
Applied Technologies, Oak Ridge, TN, USA). Cyclic voltammograms were acquired under aerobic 
conditions after having covered the electrode with 100 μL of PBS 100 mM (PBS 10×, pH 7.4) or 
human serum and adding drug samples at different concentrations. The potential was swept in the 
range from −600 mV to +300 mV vs. Ag/AgCl using a scan rate of 20 mV/s. We use a scan rate of 20 
mV/s to control the capacitive current [28]. The procedure described in [29] is used to determine peak 
current values. Detection limit and sensitivity were the key parameters used for evaluating the measure 
quality. The sensitivity was determined as the slope of the calibration line which interpolates 
experimental data. According to existing approaches [30,31], the detection limit was calculated as 
three-times the signal-noise ratio (i.e., three-times the ratio of the signal standard deviation obtained in 
the absence of the analyte over the slope of the calibration curve). Both the sensitivity and limit of 
detection were evaluated inside the linear range of each calibration curve.  
3. Results and Discussion 
3.1. Electrode Nanostructuration 
Typical scanning electron microscopy (SEM) images of the surface of a graphite electrode after the 
deposition of 30 µg of MWCNTs (A) and the deposition of one layer (B) of cytochrome P4503A4, are 
depicted in Figure 1. After the deposition of the CNT-solution (Figure 1(A)), the chloroform 
evaporates and the nanotubes lay down on the electrode surface forming a 3D porous structure made 
by agglomerates of wrapped wires randomly spread onto the surface. After the deposition of one layer 
of protein (Figure 1(B)), an increase in CNT-diameter size (of about 10 ± 4 nm) is observed, 
demonstrating that nanotubes are completely surrounded by a protein layer. With subsequent 
depositions of cytochrome P450 solutions, a lot of charging problems occurred (images not shown), 
causing significant image distortion and compromising the quality of SEM image acquisition, although 
this phenomenon demonstrates that there is an accumulation of the enzyme on the electrode surface.  
The electrochemical response of the sensor was evaluated by cyclic voltammetry measurements 
under aerobic conditions in 100 μL of PBS 10× (pH 7.4), as the supporting electrolyte. In the absence 
of the CYP substrate, cytochrome P450 can react with oxygen when a redox potential is applied to the 
electrode. This reaction can be quantified by analyzing the reduction peaks in cyclic voltammetry 
measurements. The faradic current associated with the reduction peak is dependent on the quantity of 
CYP immobilized onto the electrode and the peak potential is influenced by the immobilization 
technique. The mechanism of the reaction between the immobilized onto the electrode surface CYP 
and oxygen is outlined in [32]. When the drug (substrate) is added to a buffer solution in presence of 
oxygen, a further increase in the CYP reduction current is observed.  
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Figure 1. SEM images of graphite electrode after the drop-casting deposition of MWCNTs 
(A), and after the deposition of one layer (B) of a solution of cytochrome P4503A4. All 
images were acquired by using scanning electrode microscope in ultra-high resolution 
mode. Figure 1(A,B) was acquired with a 100,000× magnification. 
 
Current peaks and the related potential positions obtained from cyclic voltammetry acquired in PBS 
for 1-2-3-4 CYPs depositions are reported in Table 1. The maximum current is shown to increase with 
the growing number of depositions, demonstrating the improvement of the sensitivity through the 
multi-layer protein deposition, also confirmed by SEM images. Nanostructuring electrodes with 
MWCNTs lead to an enhancement in the catalytic current since nanotubes and enzyme molecules are 
of similar dimensions, promoting the enzyme adsorption without significant loss of its shape or 
catalytic activity. It is thought that physical adsorption of enzymes onto carbon nanotubes enables a 
direct electron transfer between the electrode and the active site of the redox-enzyme, minimizing  
the electron tunneling distance [33]. Moreover, the three-dimensional structure formed by the  
carbon-nanotubes onto the electrode surface provides a surface area larger than the bare electrode 
surface, with a consequent increase in the amount of adsorbed enzyme, a deeper penetration of the 
electrolytes solution and also a larger surface disposable for the redox reaction. 
Table 1. Current peaks and the related potential positions obtained with cyclic voltammetry 
in PBS for different number of CYP3A4 depositions. 
N° Layers Potential (mV) Max current value (nA) 
1 −414 ± 12 18 ± 97 
2 −390.7 ± 4.7 727 ± 13 
3 −384.0 ± 4.6 1168 ± 20 
4 −391.4 ± 4.4 1519 ± 23 
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3.2. Enzyme Adsorption  
In order to investigate the enzyme adsorption onto carbon nanotubes, we performed numerical 
simulations. With Monte Carlo simulations, we obtained the average diameter of carbon nanotubes 
after the cytochrome P450 solution has been cast onto carbon nanotubes randomly spread on the 
graphite surface of screen-printed electrodes. 
Crystallographic studies on the binding energy in antigen-antibody complexes [34] revealed that the 
binding specificity and the physical forces involved in the protein-protein complexes formation can be 
quantified through the estimation of changes in the Gibbs free energy and in principle, be applied to a 
wide range of macromolecular systems and protein-surfaces interactions, such as between cytochrome 
P450 and carbon nanotubes. Similar to studies related to the antigen-antibody interaction, we can write 
the free energy associated with the protein-CNT complex as a function of different sources of 
interactions [34]: 
.EL CF TR IDG H H T S T S T SΦΔ = Δ + Δ − Δ − Δ − Δ  (1) 
In Equation (1), we have different terms relating to different sources of the antigen-antibody 
interaction. ΔHΦ is due to the hydrophobic interactions, ΔHEL accounts for the Van der Waals forces, 
ΔSCF is the variation of the conformational entropy, ΔSTR is the variation of the entropy associated with 
the loss of translational and rotational degree of freedom by the protein P450, and ΔSID is the variation 
of the entropy associated with a mole of pure water that stabilizes the cytochrome P450-CNT 
interaction. The major contributor in Equation (1) is the hydrophobic interactions between the two 
surfaces from two different molecules (the CYP and the carbon nanotube) that participate in the bond. 
The term due to the hydrophobic interactions ΔHΦ may be computed as [34]: 
.contactH AαΦΔ =  (2) 
Equation (2) shows that the enthalpy related to hydrophobic interactions is proportional to the 
contact area between the antibody and the antigen. This enthalpy is related to the solvent-accessible 
surface of the side chains of the two structures forming the complex. Direct experiments have  
shown that 1 Å2 of buried surface corresponds to 104.5 J/mol in case of antibody/antigen hydrophobic 
interactions. Consequently, the coefficient of proportionality in Equation (2) has been empirically 
determined as: 
2104.5 /  .kJ mol nmα = −  (3) 
In order to roughly estimate the bond strength between the P450 and the carbon nanotube we can 
compare the enthalpy estimated by (2) with those for the antigen-antibody interactions. Typical contact 
area in the antigen-antibody interaction ranges from 150 Å2 up to 690 Å2. Consequently, Equations (2) 
and (3) describe a range for the hydrophobic enthalpy from −16 kJ/mol up to −74 kJ/mol. It is known 
from crystallographic studies that cytochrome P450s have a triangular prismatic shape (Figure 2) with 
approximate dimension of 4.5–5 nm × 5–6.5 nm and a thickness of 3.5–4.5 nm [35,36]. Thus, for 
cytochrome P450-CNT interaction we can estimate a contact area in the range 272 Å2–378 Å2, which 
corresponds to a hydrophobic enthalpy between −28 kJ/mol and −40 kJ/mol. These enthalpies are in the 
same order of magnitude of antigen-antibody interaction, demonstrating that hydrophobic interactions 
play an important role in determining the cytochrome P450 attachment onto the CNT surface. 
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Figure 2. Orientation of microsomal cytochrome P450 3A4 on carbon nanotubes and its 
crystallographic structure. Figure 2(A) represents the most likely orientation of cytochrome 
onto the carbon nanotube according to the percentage of hydrophobic sites reported in 
Figure 2(C). A distinct triangular prismatic shape is evident, while the hydrophobic residues 
are highlighted in blue. For the construction of the model for Monte Carlo simulations, it 
has been assumed that cytochrome molecules mainly expose their larger face (i.e., the lateral 
face, Figure 2(A)), for hydrophobic interaction with carbon nanotubes walls, since it is not 
possible to predict the right protein orientation onto the nanotube walls. Figure 2(B) 
represents four other possible orientations of cytochrome onto the carbon nanotube. 
 
The interaction between cytochrome P450 and carbon nanotubes is difficult to predict, since 
cytochrome presents on the surface several hydrophobic sites formed by N-terminal domain residues, 
hydrophobic residues [37], and also by the C-terminal end of the F-G loop [38], whereas other surfaces 
of the protein are mostly hydrophilic. It is known [39] that cytochrome basically interacts with its 
reaction partners as well as with biological membranes, through electrostatic forces and hydrophobic 
interactions. In both cases, the establishment of these interactions induces functionally relevant 
changes in the cytochrome structure [37].  
Several works [37,38,40] have reported that cytochrome P450 appears to be mono-facially attached 
to the membrane via a broad hydrophobic surface adjacent to the anchor provided by a transmembrane 
helix at the N-terminus, thus becoming partially buried in the membrane phospholipidic bilayer [38]. 
Studies with cytochrome P450 immobilized through physical adsorption onto gold surfaces [35], or 
onto a Self-Assembled-Monolayer (SAM) of methyl-terminated alkanethiols [39], demonstrated that 
hydrophobic interactions are generated between hydrophobic residues of the protein and the hydrophobic 
surfaces. These hydrophobic interactions lead to a non-specific and largely random orientation of the 
immobilized enzymes, even if it has been demonstrated that cytochromes preferentially adopt a largely 
uniform orientation that is favorable for a rapid electron transfer [39].  
Other studies [41] reported that enzymes, such as cytochrome c are suitable for self-assembly onto 
metal surfaces due to their specific and non-uniform charge surface distribution and, in particular, it 
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has been demonstrated that proteins, such as streptavidin have the tendency to self-organize around 
multi-walled carbon-nanotubes due to the amine groups of protein residues, which interacts with the 
hydrophobic sites of CNTs [42].  
For Monte Carlo simulations, we assumed that a high percentage of CNTs expose their walls for 
protein adsorption. The agglomerates of CNT after they have been drop casted onto the electrode 
surface are shown in Figure 1(A). This behavior, described in [43], is due to the fact that the ends of 
carbon nanotubes are quite hydrophilic, but the walls, which comprise the majority of the tube, are 
highly hydrophobic. Adsorbed CNTs are not completely embedded into the electrode material as in 
carbon-nanotubes paste electrodes [44,45].  
For protein adsorption, we reasonably assumed that the enzyme generates a self-assembled 
monolayer with a largely random orientation. In this case, the most important contribution to the Gibbs 
free energy changes (associated with the non-covalent cytochrome-CNT complex formation), is the 
hydrophobic effect, which is directly proportional to the solvent-accessible surface area at the  
solvent-solute interface. The difference between solvent-accessible surfaces of free and complex 
molecules provides the contact area of the complex. Therefore, for Monte Carlo simulations we 
assume that the probability of cytochrome attachment onto a specific hydrophobic site of CNT wall is 
directly proportional to its contact area (Figure 2(C)) and also that the adsorption of molecules of 
cytochrome P450 3A4 onto CNTs, considered as substrate, mimics the formation of the self-assembled 
monolayers (SAM). 
Table 2 reports results from Monte Carlo simulations compared with the measurements obtained 
from SEM images, demonstrating the capability of this model to describe the physical adsorption of 
cytochrome onto multi-walled carbon-nanotubes.  
Table 2. Average diameters of MWCNTs covered by a cytochrome P4503A4 monolayer, 
obtained by measurements on SEM images and Monte Carlo simulations. 
Measurements SEM images 20 ± 3 nm 
Monte Carlo simulations 20 ± 4 nm 
Moreover, with these simulations we obtained an average thickness for the enzyme adsorbed on the 
nanotube between 3 nm and 6 nm. These values are consistent with the size of a cytochrome P450 
molecule, also considering the possible different orientations when adsorbed. This thickness range 
demonstrates that a single protein layer homogeneously covers the carbon nanotube walls (as in the 
SEM image reported in Figure 1(B)). 
3.3. Bio-Detection Mechanism 
The biosensing mechanism is mainly based on the biochemical reaction plotted in Figure 3 where a 
cytochrome P450 transforms the redox form of a drug (cyclophosphamide in the example) in its 
oxidized form by using one oxygen molecule and two electrons. In voltammetric measurements, the 
two electrons, which in nature are provided to the enzyme by NADPH molecules [3], are supplied by 
the flowing current coming from the electrode. The detection mechanism is the measurement of the 
current produced at the electrode surface due to the redox reaction of the enzyme when a substrate is 
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present in the sample. The cyclic voltammograms show cathodic and anodic current peaks that correspond 
to the electrochemical signal registered during the redox reaction catalyzed by the cytochrome. 
Figure 3. Schematic representation of the drug detection mechanism enhanced by  
carbon nanotubes. The example illustrates the reaction of hydroxylation for the anti-cancer  
drug cyclophosphamide. 
 
Multi-walled carbon nanotubes are used for enhancing the electron transfer [17]. Electronic 
properties of MWCNTs suggest that they can promote electron-transfer reactions when used as the 
electrode material in electrochemical reactions. Other studies demonstrated that CNTs can also 
enhance the electrochemical reactivity of proteins or enzymes with retention of their biocatalytic 
activity [17,20], thus making them suitable to be integrated into biological sensors [46]. The CNTs 
current-enhancement effect is illustrated in Figure 4, where we compare the voltammetric response 
recorded for a CNT-nanostructured electrode and for a bare electrode, in presence of Etoposide  
100 μM. As can be seen, two well-defined oxidation peaks and two reduction peaks are observable in 
the voltammetric response for the CNT electrode, while the bare electrode exhibits a voltammogram 
with a smaller capacitive current and reduced current peaks. In Figure 4 the improvement of analytic 
performances with the nanostructures in comparison with the bare electrode is clearly shown. 
Furthermore, multi-walled carbon nanotubes exhibit good electronic communication with redox 
proteins immobilized on the electrode surface [17,20]. 
Figure 4. Comparison between cyclic voltammograms obtained with bare electrode (black 
curve) and CNT-nanostructured electrode (grey curve), in presence of etoposide 100 μM. 
The peak at around −200 mV is due to the oxygen moieties derived from carbon-nanotubes 
as reported in [5,47]. Two oxidation peaks at +220 mV and +450 mV and two reduction 
peaks at +150 mV and +350 mV are visible. These data confirm the peaks reported in 
literature [48], obtained through etoposide cyclic voltammetry at glassy carbon electrode. 
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3.4. Drug Detection in Buffer Solution and Human Serum 
After having considered several drugs and the related pharmacological range, we selected four 
compounds: cyclophosphamide, etoposide, ftorafur, and ifosfamide. These four drugs have been 
chosen because they have sufficiently high and wide pharmacological ranges, compatible with the 
detection limit of the measurement setup. To investigate the feasibility of our system for drug 
detection, we tested it with these drugs using three different P450 isoforms (CYP1A2, CYP2B6 and 
CYP3A4). The measurements were performed in PBS (pH 7.4) and in human serum. Voltammetric 
responses for each cytochrome-drug pairs were firstly acquired in absence of drug and then in presence 
of the drug in increasing concentration within their pharmacological range. The voltammetric 
responses to increasing aliquots of drugs and the calibration curves of the sensors are reported in 
Figure 5. The sensor potential for measuring the presence of drugs with different P450 isoforms is 
demonstrated in Table 3, which compares the results obtained in PBS and in human serum. Detection 
limit and sensitivity were the key parameters used to evaluate the quality of measurements. Detection 
limit and sensitivity have been evaluated within the linear range of the calibration curves. The 
voltammograms exhibited two cathodic peak regions at potentials centered around −330 mV and  
−450 mV, respectively. The current responses reported in Figure 5 have been measured at a cathodic 
peak potential of around −450 mV for each CYP-electrode (the corresponding data of sensitivities and 
limits of detection are not reported). The current responses reported in Table 3 have been measured at 
a cathodic peak potential around −330 mV vs. Ag/AgCl for each drug in the pharmacological range. 
For the CNT-electrode (for Etoposide detection), the current response reported in Figure 5(A) has been 
measured at an anodic peak potential of around +220 mV. Moreover, we obtained values of detection 
limits within the therapeutic range for each drug, and also sensitivities that are comparable with the 
results shown by other authors with CYP-based sensors [6–8,49–54]. 
Figure 5. Cyclic voltammetric responses (on the left) and calibration curves (on the right), 
obtained from cyclic voltammetric measurements in PBS with increasing aliquots of drugs: 
CNT-electrode for etoposide (A), cytochrome P4503A4 for ifosfamide (B), cytochrome 
P4502B6 for cyclophosphamide (C), and P4501A2 for ftorafur (D). For the CNT-electrode 
the zoom in the oxidation peak at 220 mV is shown (A, on the left). For the electrodes 
modified with cytochromes we report the zoom of the reduction peak at −450 mV (B, C, and 
D, on the left). The measured drugs concentration falls in their pharmacological range. The 
voltammograms were acquired with drugs dissolved in PBS and at the scan rate of 20 mV/s. 
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Figure 5. Cont. 
 
Table 3. Performances of electrodes nanostructured with CNTs and different CYP 
isoforms for drug detection. 
Drugs 
Pharmacological 
range (μM) 
P450 
enzyme 
Sensitivity 
(nA/μM*mm2) 
Detection limit (μM) 
PBS Serum PBS Serum 
Cyclophosphamide 2.68–76.6 [55] 
2B6 1.0 ± 0.0 0.3 ± 0.1 2.4 ± 0.0 13.8 ± 4.3 
3A4 0.6 ± 0.0 0.3 ± 0.0 4.9 ± 0.3 10.8 ± 1.8 
Ifosfamide 10–160 [56] 
2B6 1.2 ± 0.0 0.1 ± 0.0 2.8 ± 0.1 40 ± 18 
3A4 1.6 ± 0.0 0.4 ± 0.0 2.0 ± 0.0 7.1 ± 0.5 
Ftorafur 1–10 [57] 1A2 8.8 ± 0.7 3.9 ± 0.5 0.7 ± 0.1 0.8 ± 0.1 
Etoposide 33.98–101.94 [58] - 73.7 ± 0.0 9.1 ± 0.1 0.05 ± 0.0 0.5 ± 0.0 
As expected, the system exhibits better performance in PBS than in serum. However, for both cases 
the limits of detection are within the pharmacological ranges for all the tested drugs, proving the 
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feasibility of P450-based biosensor for measurements in human plasma. In these results it is evident 
that current peaks appear to be partially or totally modified by the presence of serum proteins, as 
another work has also showed [59]. The decrease in sensitivity obtained in serum can be reasonably 
attributed to the plasma proteins, such as albumin, bilirubin or hemoglobin, which can bind and 
interact with drug molecules, reducing the free drug concentration at the electrode surface, as already 
reported [60,61]. In case of ftorafur for example, it was reported that it weakly binds only to plasma 
protein (about 22%) [62], while etoposide is one of the few anti-cancer drugs that strongly binds 
(>90%) to plasma proteins [63]. Cyclophosphamide and ifosfamide exhibit relatively low protein 
binding. The active metabolites of these drugs, however, have been found to significantly bind blood 
protein, such as albumin and hemoglobin, up to 40% [60]. Plasma proteins can also be not-specifically 
adsorbed on the electrode surface and partially block the binding site of the enzyme, thus further 
reducing the signal. 
3.5. Multiple Drug Detection 
The possibility to detect the presence of two drugs in the sample has been investigated with cyclic 
voltammetric measurements obtained by the addition of cyclophosphamide, ifosfamide, and ftorafur in 
the presence of etoposide at fixed concentrations (0–25–50–75–100 μM). According to the possible 
chemotherapy regimens administered for the treatment of breast-cancer, three sets of paired drugs were 
tested (cyclophosphamide-etoposide, ifosfamide-etoposide, and ftorafur-etoposide), since they were 
the only possible drug pairs that may interact because they are metabolized by the same isoform. The 
results are reported in Figure 6, which compares the families of calibration curves obtained for three 
different P450-CNT electrodes: CYP3A4 for ifosfamide (A), CYP3A4 for cyclophosphamide (B), and 
CYP1A2 for ftorafur (C). A well-defined increase in the sensitivity with etoposide concentration is 
visible in each case. This behavior is probably due to a partial hetero-activation effect of etoposide on 
CYP3A4 and CYP1A2-mediated metabolism of the other drugs [64,65]. Several CYP isoforms, 
including 3A4, 1A2, 2E1, 2D6, and 2C9, have been reported to exhibit allotropic kinetics in vitro [9]. 
This atypical kinetic behavior is exhibited by enzymes with multiple substrate recognition sites, such 
as CYPs, and it is basically due to conformational or chemical changes that occur in the active site  
of the enzyme after binding a first substrate. These changes in the conformation of enzyme tertiary  
and quaternary structures result in the enzyme catalytic activity alteration which can affect the  
metabolism of a second substrate [10]. In Figure 6(D), each calibration curve has been obtained by 
cyclic voltammetry measurements at increasing etoposide concentration with a fixed concentration of 
ifosfamide. This plot shows that the increase in ifosfamide concentration does not affect Etoposide 
detection and this is indicated by the overlap of the calibration curves. Figure 6(D) confirms the 
specificity of the CNT electrode in detecting etoposide, even in presence of a second drug (similar 
curves have been obtained with CP and ftorafur, data not shown). Consequently, measuring etoposide 
concentration with a CNT-electrode would give us the possibility to indirectly obtain the concentration 
of the second compound (cyclophosphamide, ifosfamide or ftorafur), that might be present in the same 
blood sample.  
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Figure 6. Calibration curve families. Cyclic voltammetric measurements, in PBS, obtained 
for all drugs in their pharmacological range and etoposide at fixed concentrations  
(0–25–50–75–100 μM). Cytochrome P4503A4 was used for ifosfamide (A), cytochrome 
P4503A4 for cyclophosphamide (B), and cytochrome P4501A2 for ftorafur (C). 
Calibration curves for etoposide detection in its pharmacological range obtained with a 
CNT-electrode in presence of ifosfamide at fixed concentrations (0–40–80–120–160 μM) 
are illustrated in (D). 
 
4. Conclusions 
In this work we demonstrated that a biosensor based on cytochrome P450 (CYP1A2, CYP2B6 and 
CYP3A4) and carbon-nanotubes enable the identification of different anti-cancer drugs, thus providing 
an innovative solution for point-of-care drug monitoring. The results show sensitivities in the range of 
8–925 nA/µM. With these high sensitivities, we could perform a selective electrochemical detection of 
drugs in their therapeutic window. We showed how proteins arrange themselves in a monolayer onto 
the carbon-nanotubes surface, and we verified this behavior both with Monte Carlo simulations and 
SEM analysis. The use of three different CYP isoforms can provide specific drug detection, 
overcoming the lack of specificity for a single substrate typical of cytochrome P450. In this work, we 
perform a preliminary study for the realization of an array-sensor based on cytochrome P450. The 
main goal was to demonstrate the suitability of such sensor for detecting anti-cancer drugs within the 
pharmacological range in human serum. We also demonstrate that detection of two drugs at the same 
time can be achieved with an accurate selection of the isoform as enzyme probe according to the drug 
to be detected. Future work includes the realization of an array-based sensor, a study of kinetics and 
drug-drug interaction on the same enzyme, and a system-level analysis of the sensor in order to 
consider possible interferences. We conclude that these P450-based sensors represent a powerful  
nano-technology able to perform drug detection directly in human plasma, which can be successfully 
used to develop point-of care and low cost devices for personalized therapy. 
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